Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance

Blood (2022) 140 (Supplement 1): 264–265.

https://doi.org/10.1182/blood-2022-163654

Published: 2022

Journal Articles

Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma

Fumou Sun, Yan Cheng, Bailu Peng, Hongwei Xu, Frits van Rhee, Siegfried Janz, Guido Tricot, John D Shaughnessy, Jr., Fenghuang Zhan

Blood (2021) 138 (Supplement 1): 2802.

https://doi.org/10.1182/blood-2021-148543

Published: 2021

Journal Articles

NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma

Yan Cheng, Fumou Sun, Huojun Cao, Dongzheng Gai, Bailu Peng, Hongwei Xu, Frits van Rhee, Siegfried Janz, Guido Tricot, John D Shaughnessy, Jr., Fenghuang Zhan

Blood (2021) 138 (Supplement 1): 2671.

https://doi.org/10.1182/blood-2021-148659

Published: 2021

Journal Articles

N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma

Shiqiao Ye, Yu Chen, Bo Hu, Huayu Huang, Yuxiao Sun, James P Stewart, Sarah K Johnson, Bart Barlogie, Maurizio Zangari, Guido Tricot, Faith E Davies, Gareth J Morgan, Brian A Walker, Fenghuang Zhan, Frits van Rhee, John D Shaughnessy, Jr., Ya-Wei Qiang

Blood (2021) 138 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2021-148624

Published: 2021

Journal Articles

Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome

Meera Mohan, Zimu Gong, Samantha Kendrick, Sharmilan Thanendrarajan, Carolina Schinke, Daisy Alapat, Guido Tricot, Fenghuang Zhan, Frits van Rhee, Jeffery R. Sawyer, Erming Tian, Maurizio Zangari

Blood (2021) 138 (Supplement 1): 1627.

https://doi.org/10.1182/blood-2021-145822

Published: 2021

Journal Articles

Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance

Naveen K Yarlagadda, Meera Mohan, Shebli Atrash, Sravani Gundarlapalli, Shadiqul Hoque, Sunil Kakadia, Sharmilan Thanendrarajan, Carolina Schinke, Daisy Alapat, Guido Tricot, Erming Tian, Jeffery R. Sawyer, Fenghuang Zhan, Frits van Rhee, Maurizio Zangari

Blood (2021) 138 (Supplement 1): 2713.

https://doi.org/10.1182/blood-2021-148228

Published: 2021

Journal Articles

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Kristin Larsen, Meera Mohan, MD, Clyde Bailey, Kerri Hill, Horace Spencer, Mathew Kottarathara, MD, Richa Parikh, MD, Shadiqul Hoque, MD, Amani Erra, MD, Angel Mitma, MD, Pankaj Mathur, MD, Guido Tricot, MD PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Carolina D. Schinke, MD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-142527

Published: 2020

Journal Articles

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

Meera Mohan, MD, Samantha Kendrick, PhD, Yadav Pandey, MD, Richa Parikh, MD, Phil Farmer, Mathew Kottarathara, MD, Shadiqul Hoque, MD, Angel Mitma, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Guido Tricot, MD PhD, Maurizio Zangari, MD FACP, Frits van Rhee, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139943

Published: 2020

Journal Articles

Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT

David Baker, Milan Bimali, PhD, Luis Carrillo, MD, Archana Sachedina, Daisy Alapat, MD, Md shadiqul Hoque, MD, Mathew Kottarathara, MD, Richa Parikh, MD, Amani Erra, MD, Angel Mitma, MD, Pankaj Mathur, MD, Guido Tricot, MD PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Carolina D. Schinke, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-138877

Published: 2020

Journal Articles

RARα2 expression confers myeloma stem cell features

Ye Yang, Jumei Shi, Giulia Tolomelli, Hongwei Xu, Jiliang Xia, He Wang, Wen Zhou, Yi Zhou, Satyabrata Das, Zhimin Gu, Dana Levasseur, Fenghuang Zhan, Guido Tricot

Blood (2013) 122 (8): 1437–1447.

https://doi.org/10.1182/blood-2013-02-482919

Published: 2013

Includes: Supplemental data

Journal Articles

RARα2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma

Siqing Wang, Guido Tricot, Lei Shi, Wei Xiong, Zhaoyang Zeng, Hongwei Xu, Maurizio Zangari, Bart Barlogie, John D. Shaughnessy, Jr, Fenghuang Zhan

Blood (2009) 114 (3): 600–607.

https://doi.org/10.1182/blood-2008-12-194126

Published: 2009

Includes: Supplemental data

Journal Articles

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)

H. Miles Prince, Dirk Hönemann, Andrew Spencer, David A. Rizzieri, Edward A. Stadtmauer, Andrew W. Roberts, Nizar Bahlis, Guido Tricot, Bill Bell, Douglas J. DeMarini, A. Benjamin Suttle, Katherine L. Baker, Lini N. Pandite

Blood (2009) 113 (19): 4819–4820.

https://doi.org/10.1182/blood-2009-02-207209

Published: 2009

Journal Articles

Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma

Jumei Shi, MD, PhD, Susann Szmania, BS, Guido Tricot, MD, PhD, Tarun K. Garg, PhD, Priyangi A Malaviarachchi, BS, Amberly Moreno-Bost, BS, Katie Stone, BS, Fenghuang Zhan, MD, PhD, Dario Campana, MD, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 2758.

https://doi.org/10.1182/blood.V112.11.2758.2758

Published: 2008

Journal Articles

Parathyroid Hormones (PTH) Serum Variations Are Associated with Bortezomib Response in Multiple Myeloma Patients

Maurizio Zangari, MD, Lisa Pappas, Fenghuang Zhan, MD, PhD, Naveen Sanath kumar, MD, Federica Cavallo, MD, Larry J Suva, Guido Tricot, MD, PhD, Dixie-Lee Esseltine, MD, Shmuel Yaccoby

Blood (2008) 112 (11): 2783.

https://doi.org/10.1182/blood.V112.11.2783.2783

Published: 2008

Journal Articles

Is more better in myeloma?

Guido Tricot

Blood (2008) 112 (9): 3532.

https://doi.org/10.1182/blood-2008-06-163782

Published: 2008

Journal Articles

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Bart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, Jeff Haessler, Elias Anaissie, Klaus Hollmig, Yazan Alsayed, Sarah Waheed, Nathan Petty, Joshua Epstein, John D. Shaughnessy, Jr, Guido Tricot, Maurizio Zangari, Jerome Zeldis, Sol Barer, John Crowley

Blood (2008) 112 (8): 3115–3121.

https://doi.org/10.1182/blood-2008-03-145235

Published: 2008

Journal Articles

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

Bart Barlogie, Guido Tricot, Jeff Haessler, Frits van Rhee, Michele Cottler-Fox, Elias Anaissie, James Waldron, Mauricio Pineda-Roman, Raymond Thertulien, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, John Crowley, Jeffrey Sawyer

Blood (2008) 111 (1): 94–100.

https://doi.org/10.1182/blood-2007-06-097444

Published: 2008

Journal Articles

Coagulation-Related Effect of Bortezomib Treatment in Patients with Relapsed or Refractory Multiple Myeloma.

Maurizio Zangari, MD, Jose Guerrero, Federica Cavallo, MD, Michael J. Burns, Keshava Prasad, Dot Adcock, MD, Richard Marlar, MD, Guido Tricot, MD, Louis Fink, MD

Blood (2007) 110 (11): 2733.

https://doi.org/10.1182/blood.V110.11.2733.2733

Published: 2007

Journal Articles

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

Frits van Rhee, Vanessa Bolejack, Klaus Hollmig, Mauricio Pineda-Roman, Elias Anaissie, Joshua Epstein, John D. Shaughnessy, Jr, Maurizio Zangari, Guido Tricot, Abid Mohiuddin, Yazan Alsayed, Gail Woods, John Crowley, Bart Barlogie

Blood (2007) 110 (3): 827–832.

https://doi.org/10.1182/blood-2007-01-067728

Published: 2007

Journal Articles

An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.

John D. Shaughnessy, Jr., Jeffrey Haessler, Jerry Zeldis, Yongsheng Huang, Fenghuang Zhan, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Guido Tricot, Joshua Epstein, Maurizio Zangari, Mauricio Pineda-Roman, Klaus Hollmig, John Crowley, Bart Barlogie

Blood (2006) 108 (11): 3389.

https://doi.org/10.1182/blood.V108.11.3389.3389

Published: 2006

NARROW

A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance

Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma

NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma

N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma

Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome

Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT

RARα2 expression confers myeloma stem cell features

RARα2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)

Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma

Parathyroid Hormones (PTH) Serum Variations Are Associated with Bortezomib Response in Multiple Myeloma Patients

Is more better in myeloma?

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

Coagulation-Related Effect of Bortezomib Treatment in Patients with Relapsed or Refractory Multiple Myeloma.

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only